<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03088267</url>
  </required_header>
  <id_info>
    <org_study_id>TRI102-ADD-300</org_study_id>
    <nct_id>NCT03088267</nct_id>
  </id_info>
  <brief_title>Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study</brief_title>
  <official_title>Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children Wit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tris Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tris Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was conducted to assess the efficacy and safety of DYANAVEL XR (amphetamine
      extended-release oral suspension, CII) for the treatment of symptoms of
      attention-deficit/hyperactivity disorder (ADHD) in children aged 6-12 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, two treatment, two sequence, placebo-controlled crossover
      study to assess the efficacy and safety of dose Dyanavel XR in reducing signs and symptoms of
      ADHD compared with placebo in pediatric subjects ages 6 to 12 years with ADHD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 11, 2017</start_date>
  <completion_date type="Actual">October 30, 2017</completion_date>
  <primary_completion_date type="Actual">February 25, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a randomized, double-blind, two treatment, two sequence, placebo-controlled crossover study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>placebo-controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Combined Scores, Baseline to 30 Minutes Post Dose</measure>
    <time_frame>Change in SKAMP-C score from baseline to 30 minutes postdose.</time_frame>
    <description>Change in SKAMP-C (Swanson, Kotkin, Agler, M-Flynn, and Pelham combined) score from pre-dose, by treatment. The SKAMP-C is a rating scale that assesses functional impairment related to ADHD in the classroom, including the performance of academic tasks, following class rules, and interacting with peers and adults in the classroom. The SKAMP-C is a 13-item, 7-score rating system (0=normal to 7=maximal impairment). The higher the score, the worse the impairment. A decrease from baseline in the combined (all 13 items) score indicates improvement. The SKAMP-C is used to assess the time course of treatment effects in laboratory classroom studies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Permanent Product Measure of Performance (PERMP-C) Score (Problems Answered Correctly)</measure>
    <time_frame>30 minutes postdose and 3 hours postdose</time_frame>
    <description>Change from pre-dose in PERMP-C scores (Permanent Product Measure of Performance; defined as the number of problems attempted and number of problems solved correctly) at 30 minutes post-dose and at 3 hours post-dose. The PERMP-C is designed to assess compliance and academic productivity in school children. It is a 10-minute timed test in which the number of problems attempted and correct are assessed prior to and after an intervention. Scoring is based on problems attempted and correct. An increase in numerical score is indicative of improvement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Double blind amphetamine extended-release oral suspension, 2.5 mg/mL, 6, 7 or 8 mL po QAM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Double blind placebo, 6, 7 or 8 mL po QAM</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amphetamine extended-release oral suspension, 2.5 mg/mL</intervention_name>
    <description>5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO</description>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_label>Placebo Treatment</arm_group_label>
    <other_name>Dyanavel XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo extended-release oral suspension</intervention_name>
    <description>6, 7 or 8 mL PO</description>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_label>Placebo Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females aged 6 to 12 years at the time of screening, inclusive

          2. Diagnosed with ADHD by a psychiatrist within 6 months of study enrolment or newly
             diagnosed with ADHD using the DSM-5 criteria for ADHD

          3. An ADHD-RS-5 score at Screening ≥90th percentile for sex and age in at least one of
             the following categories:

               1. Hyperactive-impulsive subscale,

               2. Inattentive subscale, or

               3. Total score. Subjects who do not meet this criteria at screening can have
                  ADHD-RS-5 repeated at baseline, after washout of stimulant medication for a
                  minimum of 24 hours prior to baseline.

          4. In the clinical judgment of the Investigator, the subject must be in need of
             pharmacological treatment for ADHD.

          5. Females of childbearing potential must be non-lactating and must have a negative serum
             pregnancy test at screening

          6. Provide written informed consent (parent/guardian) and assent (child aged 10 - 12
             years only) prior to participation in the study

        Exclusion Criteria:

          1. Diagnosed with any DSM-5 active disorder (other than ADHD) with the exception of
             specific phobias, learning disorders, motor skills disorders, communication disorders,
             oppositional defiant disorder, elimination disorders, and sleep disorders

          2. Known history of chronic medical illnesses including severe hypertension, untreated
             thyroid disease, peripheral vasculopathy, known structural cardiac disorders, serious
             cardiac conditions, serious arrhythmias, cardiomyopathy, known family history of
             sudden death

          3. Known history or presence of significant renal or hepatic disease, as indicated by
             clinical laboratory assessment (liver function test results ≥ two times the upper
             limit of normal, blood urea nitrogen, or creatinine).

          4. Clinically significant abnormal ECG or cardiac findings on physical examination
             (including the presence of a pathologic murmur)

          5. Use of the following medications within 30 days of Baseline Visit:

               -  MAOI - monoamine oxidase inhibitors (e.g., Selegiline, isocarboxazid, phenelzine,
                  tranylcypromine)

               -  Tricyclic Antidepressants (e.g. Desipramine, protriptyline)

          6. Use of the following medications within 3 days of Baseline Visit

               -  Gastrointestinal acidifying agents (e.g., guanethidine, reserpine, glutamic acid
                  HCl, ascorbic acid)

               -  Urinary acidifying agents (e.g., ammonium chloride, sodium acid phosphate,
                  methenamine salts)

          7. Use of atomoxetine within 14 days of Baseline Visit

          8. Planned use of prohibited drugs or agents from the Screening visit through the end of
             the study

          9. Abnormal clinically significantly laboratory test value at screening that, in the
             opinion of the Investigator, would preclude study participation

         10. Known history of allergy/hypersensitivity to amphetamine or any of the components of
             Dyanavel XR, or topical anaesthetics

         11. Known history of lack of response to amphetamine

         12. Parent or guardian's inability or unwillingness to follow directions of the
             Investigator or study research staff.

         13. Any uncontrolled medical condition that in the opinion of the Investigator would
             preclude study participation

         14. History of significant illness requiring hospitalization, or surgery requiring
             anaesthetics within 30 days of Baseline Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sally Berry, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tris Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Psychiatry and Behavioral Medicine</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 9, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <results_first_submitted>May 16, 2019</results_first_submitted>
  <results_first_submitted_qc>June 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 9, 2019</results_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 2, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03088267/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03088267/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Date first subject enrolled: February 11, 2017 Date last subject completed: February 25, 2017</recruitment_details>
      <pre_assignment_details>All 18 subjects were enrolled and completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence: AMPH EROS/Placebo</title>
          <description>Patients optimized on open label dose of AMPH EROS. Randomized to optimized dose of AMPH EROS for 1 day. Laboratory classroom assessment takes place. Then crossover to placebo for 4-5 days followed by second laboratory classroom assessment.</description>
        </group>
        <group group_id="P2">
          <title>Sequence: Placebo/AMPH EROS</title>
          <description>Patients optimized on open label dose of AMPH EROS. Randomized to placebo for 1 day. Laboratory classroom assessment takes place. Then crossover to optimized dose of AMPH EROS for 4-5 days followed by second laboratory classroom assessment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>Open label phase: amphetamine extended-release oral suspension, 2.5 mg/mL at optimal dose
Double blind phase:
A single dose of amphetamine extended-release oral suspension, 2.5 mg/mL, 6, 7 or 8 mL po QAM, or placebo extended-release oral suspension: 6, 7 or 8 mL PO</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10" lower_limit="6" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Combined Scores, Baseline to 30 Minutes Post Dose</title>
        <description>Change in SKAMP-C (Swanson, Kotkin, Agler, M-Flynn, and Pelham combined) score from pre-dose, by treatment. The SKAMP-C is a rating scale that assesses functional impairment related to ADHD in the classroom, including the performance of academic tasks, following class rules, and interacting with peers and adults in the classroom. The SKAMP-C is a 13-item, 7-score rating system (0=normal to 7=maximal impairment). The higher the score, the worse the impairment. A decrease from baseline in the combined (all 13 items) score indicates improvement. The SKAMP-C is used to assess the time course of treatment effects in laboratory classroom studies.</description>
        <time_frame>Change in SKAMP-C score from baseline to 30 minutes postdose.</time_frame>
        <population>Intent to Treat Population: 18 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment</title>
            <description>Double blind amphetamine extended-release oral suspension, 2.5 mg/mL, 6, 7 or 8 mL po QAM
amphetamine extended-release oral suspension, 2.5 mg/mL: 5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO
Placebo extended-release oral suspension: 6, 7 or 8 mL PO</description>
          </group>
          <group group_id="O2">
            <title>Placebo Treatment</title>
            <description>Double blind placebo, 6, 7 or 8 mL po QAM
amphetamine extended-release oral suspension, 2.5 mg/mL: 5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO
Placebo extended-release oral suspension: 6, 7 or 8 mL PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Combined Scores, Baseline to 30 Minutes Post Dose</title>
          <description>Change in SKAMP-C (Swanson, Kotkin, Agler, M-Flynn, and Pelham combined) score from pre-dose, by treatment. The SKAMP-C is a rating scale that assesses functional impairment related to ADHD in the classroom, including the performance of academic tasks, following class rules, and interacting with peers and adults in the classroom. The SKAMP-C is a 13-item, 7-score rating system (0=normal to 7=maximal impairment). The higher the score, the worse the impairment. A decrease from baseline in the combined (all 13 items) score indicates improvement. The SKAMP-C is used to assess the time course of treatment effects in laboratory classroom studies.</description>
          <population>Intent to Treat Population: 18 subjects</population>
          <units>number of questions answered correctly</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="2.29"/>
                    <measurement group_id="O2" value="2.5" spread="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0118</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.94</ci_lower_limit>
            <ci_upper_limit>-2.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Permanent Product Measure of Performance (PERMP-C) Score (Problems Answered Correctly)</title>
        <description>Change from pre-dose in PERMP-C scores (Permanent Product Measure of Performance; defined as the number of problems attempted and number of problems solved correctly) at 30 minutes post-dose and at 3 hours post-dose. The PERMP-C is designed to assess compliance and academic productivity in school children. It is a 10-minute timed test in which the number of problems attempted and correct are assessed prior to and after an intervention. Scoring is based on problems attempted and correct. An increase in numerical score is indicative of improvement.</description>
        <time_frame>30 minutes postdose and 3 hours postdose</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment</title>
            <description>Double blind amphetamine extended-release oral suspension, 2.5 mg/mL, 6, 7 or 8 mL po QAM
amphetamine extended-release oral suspension, 2.5 mg/mL: 5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO
Placebo extended-release oral suspension: 6, 7 or 8 mL PO</description>
          </group>
          <group group_id="O2">
            <title>Placebo Treatment</title>
            <description>Double blind placebo, 6, 7 or 8 mL po QAM
amphetamine extended-release oral suspension, 2.5 mg/mL: 5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO
Placebo extended-release oral suspension: 6, 7 or 8 mL PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Permanent Product Measure of Performance (PERMP-C) Score (Problems Answered Correctly)</title>
          <description>Change from pre-dose in PERMP-C scores (Permanent Product Measure of Performance; defined as the number of problems attempted and number of problems solved correctly) at 30 minutes post-dose and at 3 hours post-dose. The PERMP-C is designed to assess compliance and academic productivity in school children. It is a 10-minute timed test in which the number of problems attempted and correct are assessed prior to and after an intervention. Scoring is based on problems attempted and correct. An increase in numerical score is indicative of improvement.</description>
          <population>Intention to treat</population>
          <units>Change from baseline in PERMP score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from predose in PERMP-C at 30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" spread="7.25"/>
                    <measurement group_id="O2" value="-4.7" spread="7.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from predose in PERMP-C at 3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" spread="9.43"/>
                    <measurement group_id="O2" value="-7.9" spread="9.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 30 minutes post-dose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1128</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>18.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.94</ci_lower_limit>
            <ci_upper_limit>42.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison at 3 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>60.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>32.91</ci_lower_limit>
            <ci_upper_limit>87.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The duration of the study (5 weeks from screening to final follow-up assessment)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AMPH EROS: Open Label Phase</title>
          <description>All AEs reported are from the open-label dose optimization phase with AMPH EROS. The open-label dose optimization phase preceded the crossover portion of the study.</description>
        </group>
        <group group_id="E2">
          <title>Crossover Phase: AMPH EROS</title>
          <description>These AEs occurred during the crossover phase of the study.</description>
        </group>
        <group group_id="E3">
          <title>Crossover Phase: Placebo</title>
          <description>These AEs occurred during the crossover phase of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visioned blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain, upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Respiratory tract viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Motion sickness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affect lability</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Constricted affect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Antonio Pardo MD</name_or_title>
      <organization>Tris Pharma, Inc.</organization>
      <phone>16107502210</phone>
      <email>apardo@trispharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

